Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor

Journal of Biomolecular Screening

Volumn 12, Issue 2, 2007, Pages 235-239

  Heise, Christopher E ^a,c   Sullivan, Susan K ^b   Crowe, Paul D ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

^b Synteract Inc   (United States)

^c Neurocrine Biosciences ^*  (United States)

Author keywords

GPCR; HTS; Kinetics; SAR; SPA

Indexed keywords

GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; LIGAND;

ACCURACY; ARTICLE; ASSAY; BINDING AFFINITY; DISSOCIATION CONSTANT; FOLLOW UP; HIGH THROUGHPUT SCREENING; KINETICS; LIGAND BINDING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SCINTILLATION; SCREENING;

BINDING, COMPETITIVE; GONADOTROPIN-RELEASING HORMONE; KINETICS; LIGANDS; RADIOLIGAND ASSAY; RECEPTORS, LHRH; SCINTILLATION COUNTING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847667536     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106297362     Document Type: Article

References (17)

1. Anderes KL, Luthin DR, Castillo R, Kraynov EA, Castro M, Nared-Hood K,, et al. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther 2003 ; 305: 688-695.
2. Tucci FC, Zhu YF, Guo Z, Gross TD, Connors PJ Jr, Struthers RS,, et al. A novel synthesis of 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimid-4-ones as potent, stable GnRH receptor antagonists. Bioorg Med Chem Lett 2002 ; 12: 3491-3495.
3. Yun-Fei Zhu CC, Struthers RS: Nonpeptide gonadotropin releasing hormone antagonists. In Doherty AM (ed): Annual Reports in Medicinal Chemistry. Paris France: Elsevier, 2004: 99-108.
4. Lacourciere Y, Asmar R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999 ; 12: 1181-1187.
5. Swinney DC: Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 2006 ; 6: 461-478.
6. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S,, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001 ; 3: 16-21.
7. Vanderheyden PM, Fierens FL, Vauquelin G: Angiotensin II type 1 receptor antagonists: why do some of them produce insurmountable inhibition? Biochem Pharmacol 2000 ; 60: 1557-1563.
8. Swinney DC: Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004 ; 3: 801-808.
9. Vauquelin G, Van Liefde I: Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006 ; 7: 355-359.
10. Copeland RA, Pompliano DL, Meek TD: Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006 ; 5: 730-739.
11. Sullivan SK, Hoare SR, Fleck BA, Zhu YF, Heise CE, Struthers RS,, et al. Kinetics of nonpeptide antagonist binding to the human gonadotropinreleasing hormone receptor: implications for structure-activity relationships and insurmountable antagonism. Biochem Pharmacol 2006 ; 72: 838-849.
12. Motulsky HJ, Mahan LC: The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 1984 ; 25: 1-9.
13. Berry J, Price-Jones M: Measurement of radioligand binding by scintillation proximity assay. Methods Mol Biol 2005 ; 306: 121-138.
14. Waelbroeck M, Camus J, Christophe J: Determination of the association and dissociation rate constants of muscarinic antagonists on rat pancreas: rank order of potency varies with time. Mol Pharmacol 1989 ; 36: 405-411.
15. Aranyi P: Kinetics of the hormone-receptor interaction: competition experiments with slowly equilibrating ligands. Biochim Biophys Acta 1980 ; 628: 220-227.
16. Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE: Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol 2003 ; 63: 751-765.
17. Kenakin T, Jenkinson S, Watson C: Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 2006 ; 319: 710-723.